4-(3-Chloropropyl)morpholine CAS 7357-67-7 Gefitinib Munditia Intermedia >98.0% (GC)
Ruifu Chemical primarius est opificem 4-(3-Chloropropyl) morpholinum (CAS: 7357-67-7) cum qualitate media gefitinib (CAS: 184475-35-2).Ruifu Chemical traditio totius terrarum, quantitatis competitive pretium, optimum servitium, parvas et moles in promptu habere potest.Purchase 4-(3-Chloropropyl) morpholine,Please contact: alvin@ruifuchem.com
| Nomen chemicum | 4-(3-Chloropropyl) morpholine |
| Synonyma | N-(3-Chloropropyl)morpholine;3-Morpholinopropyl Chloride;1-Chloro-3-(Morpholin-4-yl) propane;1-Chloro-3-Morpholinopropane;3-(Morpholin-4-yl) propyl Chloride;3-Chloro-1-(Morpholin-4-yl)propane;Impuritas Gefitinib VI |
| Stock Status | In Stock, Commercial Productio |
| CAS Number | 7357-67-7 |
| Formulae hypotheticae | C7H14ClNO |
| M. Pondus | 163.65 g/mol |
| Ferveret | 115℃/25mmHg(lit.) |
| Mico punctum | 91℃ |
| Sensitiva | Aer Sensitivus, calor Sensitivus |
| COA & MSDS | Praesto |
| Sample | Praesto |
| Origin | Shanghai, China |
| Brand | Ruifu Chemical |
| Items | Signa inspectionis | Proventus |
| Aspectus | Hyalina in luce Yellow liquida liquida | Obsequitur |
| Puritas / Analysis Methodus | >98.0% (GC) | 99.35% |
| Aquae Caroli Fischer | <0.50% | 0.26% |
| Maximurn Impuritas | <0.50% | <0.50% |
| Totalis immunditias | <2.00% | 0.65% |
| Index refractivus n20/D | 1.4705~1.4765 | Obsequitur |
| Densitas (20℃) | 1.077~1.081 | Obsequitur |
| 1 H NMR Spectrum | Congruunt Structure | Obsequitur |
| conclusio | Productum probatum est et cum datis specificationibus obsequitur | |
| Applicationem | Medium Gefitinib (CAS: 184475-35-2) | |
Sarcina:Fluorinated Utrem, 25kg/Drum, vel secundum exigentiam emptoris.
Repono Condition:Continentem arcte clausam et in frigido, sicco et bene ventilato horreis a substantiis incompossibilibus repone.A luce et humore protege.
Naviportans:Libera ad mundum ab aere, per FedEx / DHL Express.Ieiunium et certas traditiones provide.
Quam mercari?Quaeso contactumDr. Alvin Huang: sales@ruifuchem.com or alvin@ruifuchem.com
15 Years Experience?Plus quam XV annos experientiae habemus in fabricando et exportando amplis intermediis pharmaceuticis vel alchimicis pharmaceuticis amplis.
Mercatus principalis?Vendere mercatum domesticum, Americam septentrionalem, Europam, Indiam, Coream, Iaponicam, Australiam etc.
Commodi?Superior qualitas, parabilis pretium, officia professionalia et subsidia technica, ieiunium partus.
Qualitasfides?Qualitas strictioris temperantiae ratio.Pro instrumento analysi professionali includuntur NMR, LC-MS, GC, HPLC, ICP-MS, UV, IR, OR, KF, ROI, LOD, MP, Claritas, Solubilitas, Microbialis limes test, etc.
Exempla?Pleraque producta praebent exempla gratuita pro qualitate aestimationis, sumptus naviculas a clientibus solvendos.
Factory Audit?Factory audit gratissimum.Quaeso ante constitutum.
MOQ?Nec MOQ.Parvus ordo placet.
Tempus adferendi? Si intus prosapia, tres dies partus praestatur.
Transportatio?Per Express (FedEx, DHL), ab Air, per Mare.
Documenta?Post servitium venditionis: COA, MOA, ROS, MSDS, etc. praeberi possunt.
Consuetudo Synthesis?Consuetudo synthesis officia praebere potest ad optimas investigationes tuas necessitates aptandas.
Pensio conditio?Proforma cautionis primum post confirmationem ordinis mittetur, informationes nostrae ripae inclusas.Payment by T/T (Telex Transfer), PayPal, Western Union, etc.
Periculum Codes
36/37/38 - Irritando ad oculos, systema respiratorium et cutem.
Salus Descriptio
S26 - In contactu cum oculis, statim cum aqua multa ablue et consilium medicinae quaeras.
S36/37/39 - Indumentum tutelae idoneum, caestus et oculi/facies tutelam gerunt.
RTECS QE0488000
Aleam Class INRITANT
4-(3-Chloropropyl)morpholine (CAS: 7357-67-7) medium est Gefitinib (CAS: 184475-35-2).Gefitinib, medicamentum adhibitum est ad pectus, pulmonem, et alios carcinomata, etiam Iressa, factor incrementi epidermalis selectivi receptoris (EGFR) inhibitoris kinasi tyrosini, ad curationem prioris localiter progressi vel metastaticae curationis non-chemicae vel inhabilis ad chemotherapysmall cancer pulmonis cellula (NSCLC).Gefitinib est valde specifica anti-tumor iaculatorum therapiae medicamentorum, quae ab AstraZeneca in Britannia est.Primum medicamentum hypothetica iaculis est ad curationem cancri cellae pulmonis non parvae.
